Anzeige
Mehr »
Login
Dienstag, 30.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Basin Uranium: Es geht los! Der Uran-Superzyklus ist gestartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
120 Leser
Artikel bewerten:
(0)

GENEWIZ To Launch Single-Cell RNA-Seq Services At AACR

Full Genomics Capabilities Including High Throughput Genomics, Sanger Sequencing, Synthetic Biology, and GLP-Compliant Services Also Showcased

SOUTH PLAINFIELD, New Jersey and WASHINGTON, March 28, 2017 /PRNewswire/ --(AACR17, Booth #3431)- Leading global genomics service provider, GENEWIZ,will launch single-cell sequencing during the American Association for Cancer Research (AACR) Annual Meeting at the Walter E. Washington Convention Center in Washington, D.C., April 1-5, 2017. Single-Cell RNA-Seq allows researchers to perform differential gene expression of thousands of cells at the individual level.

Photo - http://mma.prnewswire.com/media/483486/GENEWIZ_Single_Cell_RNA.jpg

Highlights:

  • Experts on-hand at AACR to discuss expanded next generation sequencing service offerings for cancer researchers including single-cell sequencing with the 10x Genomics® Chromium', and whole genome sequencing with the Illumina HiSeq' X Ten and the PacBio® Sequel.
  • Show-only discounts on GENEWIZ's complete service offering including: next generation and Sanger sequencing, gene synthesis, and GLP-compliant services.
  • Poster presentation in conjunction with Celsee Diagnostics:
    "Enrichment and Mutation Detection of Circulating Tumor Cells from Blood Samples"
    Liquid Biopsies 1: Circulating Tumor Cells
    Monday, April 3 -- 8 a.m. to Noon
    Poster Section 30 / Poster Board 10

"We are excited to introduce our new single-cell sequencing workflow at AACR as it will bring cancer researchers complete access to critical molecular information down to the cellular level," said Dr. Ginger Zhou, director of genomics and molecular genetics, GENEWIZ. "AACR brings together the best and the brightest in cancer research, making it an excellent opportunity for us to collaborate on new technologies and proprietery protocols that will help scientists advance their discoveries faster than ever before and ultimately transform cancer genomics."

About GENEWIZ
GENEWIZ is a global leader in genomics services that enable research scientists within pharmaceutical, biotechnology, agriculture, environmental and clean energy, academic, and government institutions to advance their discoveries. Customers rely on our unique and proprietary genomics technologies and services, backed by our specialized experts in DNA sequencing, gene synthesis, molecular biology, high throughput sequencing, bioinformatics, and GLP regulatory-compliant services.

Headquartered in South Plainfield, NJ, GENEWIZ is privately-held with a global network of laboratories in Boston, MA; Washington, D.C. Metro; Research Triangle Park, NC; San Diego, CA; Los Angeles, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, Suzhou, and Tianjin, China; Takeley, United Kingdom; and Tokyo, Japan. For more information, visit www.genewiz.com, and connect with us on LinkedIn, Twitter, Facebook, YouTube, WeChat, and Weibo.

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.